483 related articles for article (PubMed ID: 20231388)
21. Rapid development of Candida krusei echinocandin resistance during caspofungin therapy.
Forastiero A; Garcia-Gil V; Rivero-Menendez O; Garcia-Rubio R; Monteiro MC; Alastruey-Izquierdo A; Jordan R; Agorio I; Mellado E
Antimicrob Agents Chemother; 2015 Nov; 59(11):6975-82. PubMed ID: 26324281
[TBL] [Abstract][Full Text] [Related]
22. Successful treatment of an infant infected with refractory C. parapsilosis with caspofungin.
Ozkaya-Parlakay A; Tezer H; Kazmacan T; Gulhan B; Unal S
J Trop Pediatr; 2014 Aug; 60(4):329-30. PubMed ID: 24567311
[TBL] [Abstract][Full Text] [Related]
23. Caspofungin susceptibility testing of isolates from patients with esophageal candidiasis or invasive candidiasis: relationship of MIC to treatment outcome.
Kartsonis N; Killar J; Mixson L; Hoe CM; Sable C; Bartizal K; Motyl M
Antimicrob Agents Chemother; 2005 Sep; 49(9):3616-23. PubMed ID: 16127030
[TBL] [Abstract][Full Text] [Related]
24. Seven-year trend analysis of nosocomial candidemia and antifungal (fluconazole and caspofungin) use in Intensive Care Units at a Brazilian University Hospital.
Girão E; Levin AS; Basso M; Gobara S; Gomes LB; Medeiros EA; Costa SF
Med Mycol; 2008 Sep; 46(6):581-8. PubMed ID: 19180727
[TBL] [Abstract][Full Text] [Related]
25. Outcomes by
Locke JB; Pillar CM; Castanheira M; Carvalhaes CG; Andes D; Aram JA; Andrzejewski C; Bartizal K; Das AF; Sandison T; Thompson GR; Pappas PG
Antimicrob Agents Chemother; 2024 May; 68(5):e0158423. PubMed ID: 38526046
[TBL] [Abstract][Full Text] [Related]
26. Elevated chitin content reduces the susceptibility of Candida species to caspofungin.
Walker LA; Gow NA; Munro CA
Antimicrob Agents Chemother; 2013 Jan; 57(1):146-54. PubMed ID: 23089748
[TBL] [Abstract][Full Text] [Related]
27. Pharmacoeconomic analysis of antifungal therapy for primary treatment of invasive candidiasis caused by Candida albicans and non-albicans Candida species.
Ou HT; Lee TY; Chen YC; Charbonneau C
BMC Infect Dis; 2017 Jul; 17(1):481. PubMed ID: 28693479
[TBL] [Abstract][Full Text] [Related]
28. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods.
Pfaller MA; Boyken L; Hollis RJ; Messer SA; Tendolkar S; Diekema DJ
J Clin Microbiol; 2006 Oct; 44(10):3533-8. PubMed ID: 17021079
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species.
Pfaller MA; Messer SA; Mills K; Bolmström A; Jones RN
J Clin Microbiol; 2001 Dec; 39(12):4387-9. PubMed ID: 11724849
[TBL] [Abstract][Full Text] [Related]
30. Epidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008.
Pfaller MA; Andes DR; Diekema DJ; Horn DL; Reboli AC; Rotstein C; Franks B; Azie NE
PLoS One; 2014; 9(7):e101510. PubMed ID: 24991967
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of micafungin for the treatment of invasive candidiasis and candidaemia in patients with neutropenia.
Chandrasekar P; Sirohi B; Seibel NL; Hsu JW; Azie N; Wu C; Ruhnke M
Mycoses; 2018 May; 61(5):331-336. PubMed ID: 29364548
[TBL] [Abstract][Full Text] [Related]
32. Effects of caspofungin against Candida guilliermondii and Candida parapsilosis.
Barchiesi F; Spreghini E; Tomassetti S; Della Vittoria A; Arzeni D; Manso E; Scalise G
Antimicrob Agents Chemother; 2006 Aug; 50(8):2719-27. PubMed ID: 16870764
[TBL] [Abstract][Full Text] [Related]
33. New echinocandin susceptibility patterns for nosocomial Candida albicans in Bogotá, Colombia, in ten tertiary care centres: an observational study.
Rodríguez-Leguizamón G; Fiori A; Lagrou K; Gaona MA; Ibáñez M; Patarroyo MA; Van Dijck P; Gómez-López A
BMC Infect Dis; 2015 Feb; 15():108. PubMed ID: 25888031
[TBL] [Abstract][Full Text] [Related]
34. C. albicans, C. parapsilosis and C. tropicalis invasive infections in the PICU: clinical features, prognosis and mortality.
Jordán I; Hernandez L; Balaguer M; López-Castilla JD; Casanueva L; Shuffelman C; García-Teresa MA; de Carlos JC; Anguita P; Aguilar L;
Rev Esp Quimioter; 2014 Mar; 27(1):56-62. PubMed ID: 24676244
[TBL] [Abstract][Full Text] [Related]
35. Antifungal susceptibility profiles of bloodstream yeast isolates by Sensititre YeastOne over nine years at a large Italian teaching hospital.
Posteraro B; Spanu T; Fiori B; De Maio F; De Carolis E; Giaquinto A; Prete V; De Angelis G; Torelli R; D'Inzeo T; Vella A; De Luca A; Tumbarello M; Ricciardi W; Sanguinetti M
Antimicrob Agents Chemother; 2015 Jul; 59(7):3944-55. PubMed ID: 25896705
[TBL] [Abstract][Full Text] [Related]
36. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients.
Zaoutis TE; Jafri HS; Huang LM; Locatelli F; Barzilai A; Ebell W; Steinbach WJ; Bradley J; Lieberman JM; Hsiao CC; Seibel N; Laws HJ; Gamba M; Petrecz M; Taylor AF; Strohmaier KM; Chow JW; Kartsonis NA; Ngai AL
Pediatrics; 2009 Mar; 123(3):877-84. PubMed ID: 19255017
[TBL] [Abstract][Full Text] [Related]
37. Caspofungin in the treatment of symptomatic candiduria.
Sobel JD; Bradshaw SK; Lipka CJ; Kartsonis NA
Clin Infect Dis; 2007 Mar; 44(5):e46-9. PubMed ID: 17278048
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of caspofungin in invasive candidiasis and candidemia--de-escalation strategy.
Lichtenstern C; Nguyen TH; Schemmer P; Hoppe-Tichy T; Weigand MA
Mycoses; 2008; 51 Suppl 1():35-46. PubMed ID: 18471160
[TBL] [Abstract][Full Text] [Related]
39. Monotherapy with caspofungin for candidaemia in adult patients with cancer: a retrospective, single institution study.
Sipsas NV; Lewis RE; Raad II; Kontoyiannis DP
Int J Antimicrob Agents; 2009 Jul; 34(1):95-8. PubMed ID: 19251404
[TBL] [Abstract][Full Text] [Related]
40. [Isolation rate and susceptibilities of candida species from blood, vascular catheter, urine and stool].
Tashiro M; Murakami H; Yoshizawa S; Tateda K; Yamaguchi K
Kansenshogaku Zasshi; 2012 Mar; 86(2 Suppl 4):15-20. PubMed ID: 23115940
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
